Compare AMPG & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPG | TIL |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.1M | 74.7M |
| IPO Year | N/A | 2021 |
| Metric | AMPG | TIL |
|---|---|---|
| Price | $2.55 | $8.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | ★ 498.5K | 48.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.54 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $168.18 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.21 | $5.67 |
| 52 Week High | $4.89 | $42.75 |
| Indicator | AMPG | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 39.76 | 56.36 |
| Support Level | $2.55 | $6.85 |
| Resistance Level | $2.59 | $9.81 |
| Average True Range (ATR) | 0.15 | 0.69 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 11.94 | 59.41 |
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.